Rabbit Recombinant Monoclonal PIM2 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Flow Cyt | WB | IHC-P | |
---|---|---|---|
Human | Not recommended | Tested | Not recommended |
Mouse | Not recommended | Predicted | Not recommended |
Rat | Not recommended | Predicted | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate.
Serine/threonine-protein kinase pim-2, Pim-2h, PIM2
Rabbit Recombinant Monoclonal PIM2 antibody. Suitable for WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
PIM2 also known as Pim-2 proto-oncogene encodes a serine/threonine kinase with a molecular weight of approximately 34 kDa. This protein is expressed in various tissues with higher levels in hematopoietic and lymphoid systems. PIM2 kinase activity increases under certain cellular stress conditions and it functions by phosphorylating substrates involved in cell survival proliferation and apoptosis regulation. As a member of the PIM kinase family it shares functional characteristics with its relatives PIM1 and PIM3.
The actions of PIM2 influence cell cycle progression and survival. It does not form a complex but interacts with several other proteins. PIM2 phosphorylates important substrates such as BAD and 4E-BP1 which impacts the cellular translation machinery and apoptotic pathways. Through these interactions PIM2 contributes to cellular responses to growth factors and various stress signals promoting cell survival even in low nutrient or hypoxic conditions.
In the PI3K/AKT and MYC signaling pathways PIM2 has important roles. PIM2 contributes by regulating the stability and activity of MYC a transcription factor vital for cancer cell metabolism. In the PI3K/AKT pathway PIM2 activity works synergistically with AKT to enhance pro-survival and proliferative signals. These actions link PIM2 with both cellular growth and survival pathways often cooperating with proteins like mTOR and BAD to modulate downstream effects.
Aberrant PIM2 expression has been associated with several malignancies including leukemia and multiple myeloma. The elevated PIM2 levels in cancer cells often correlate with resistance to apoptosis contributing to tumor progression. In these contexts PIM2 interacts with oncogenic proteins such as MYC and mTOR establishing a network that supports the survival and growth of tumor cells. Targeting PIM2 directly or its associated pathways offers potential therapeutic strategies for these cancers.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-PIM2 antibody [EPR6988] (ab129193) at 1/1000 dilution
Lane 1: Jurkat cell lysates at 10 µg
Lane 2: K562 cell lysates at 10 µg
Lane 3: Raji cell lysates at 10 µg
Lane 4: HL60 cell lysates at 10 µg
All lanes: Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 34 kDa
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com